Document is current
Any future updates will be listed below
-
Authors
O’Sullivan Coyne, Geraldine
Kummar, Shivaani
Rubinstein, Larry V.
Wilsker, Deborah
Moore, Nancy
Hogu, Murielle
Piekarz, Richard
Covey, Joe
Beumer, Jan H.
Ferry-Galow, Katherine V.
Villaruz, Liza C.
Hollingshead, Melinda G.
Holleran, Julianne L.
Deppas, Joshua J.
Pommier, Yves
Ko, Brian
Johnson, Barry C.
Parchhment, Ralph E.
Ivy, Percy
Doroshow, James H.
Chen, Alice P.
-
Funding
Funding for this research was provided by:
National Cancer Institute (HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E, HHSN261200800001E)
National Cancer Institute
- License Information
-
More Information
Article History
Received: 16 January 2025
Accepted: 3 May 2025
First Online: 29 May 2025
Declarations
:
: Shivaani Kummar has consultant/advisory roles with Springworks Therapeutics, SeaGen, Bayer, Genome & Company, HarbourBiomed, BPGbio Therapeutics, Oxford Biotherapeutics, Mundibiopharma, BPGbio, Inc., Gilead, Mirati, Fortress Biotech, Inc., GI Innovation, Inc., Xyone Therapeutics, Genome Insight, Aadi Biosciences, MOMA Therapeutics, Daiichi Sankyo, and Pathomiq (co-founder). Other authors declare no potential conflicts of interest.
